However, targeted therapies, such as BTK and BCL2 inhibitors, are increasingly being used to manage both low- and high-risk CLL patients, such as those marked by del(17p) or mutated TP53. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.